Last reviewed · How we verify
TESTOSTERONE ENANTHATE
At a glance
| Generic name | TESTOSTERONE ENANTHATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
Common side effects
- Myocardial infarction
- Stroke
- Venous thromboembolism
- Hepatocellular neoplasms
- Peliosis hepatis
- Bleeding in patients on concomitant anticoagulant therapy
- Polycythemia
- Anaphylactoid reactions
- Fluid and Electrolyte Disturbances
- Retention of sodium
- Retention of chloride
- Retention of water
Key clinical trials
- 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism (PHASE3)
- Working Out M0 Bipolar Androgen Therapy (PHASE2)
- Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer (PHASE2)
- Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway
- Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression (PHASE2)
- Bipolar Androgen Therapy + Carboplatin in mCRPC (PHASE2)
- Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury (PHASE2)
- Muscle Anabolic Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |